Ranbaxy, like most of India's pharmaceutical companies, has for years produced generic medicines and cheaper clones of patented drugs, but a change in Indian patent laws and an ambition to be an innovator are pushing Ranbaxy to step up its basic drug research. With its cash, early R&D investments and experience selling in the West, the company is now connecting with strong partners in its efforts to turn itself into a research-based multinational.

Full Story:

Related Summaries